Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
The Invenomic Fund experienced a challenging Q2 2025 due to a historic momentum rally and extreme growth outperformance, but remains highly confident that inevitable market normalization will reward its disciplined value-oriented positioning.
Full Quick Take
The Invenomic Fund experienced a challenging Q2 2025 due to a historic momentum rally and extreme growth outperformance, but remains highly confident that inevitable market normalization will reward its disciplined value-oriented positioning.
